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Abstract
Background: Colorectal cancer (CRC) has the third highest mortality rates among the US population. According to the most
recent concept of carcinogenesis, human tumors are organized hierarchically, and the top of it is occupied by malignant
stem cells (cancer stem cells, CSCs, or cancer-initiating cells, CICs), which possess unlimited self-renewal and tumor-initiating
capacities and high resistance to conventional therapies. To reflect the complexity and diversity of human tumors and to
provide clinically and physiologically relevant cancer models, large banks of characterized patient-derived low-passage cell
lines, and especially CIC-enriched cell lines, are urgently needed.
Principal Findings: Here we report the establishment of a novel CIC-enriched, highly tumorigenic and clonogenic colon
cancer cell line, CR4, derived from liver metastasis. This stable cell line was established by combining 3D culturing and 2D
culturing in stem cell media, subcloning of cells with particular morphology, co-culture with carcinoma associated
fibroblasts (CAFs) and serial transplantation to NOD/SCID mice. Using RNA-Seq complete transcriptome profiling of the
tumorigenic fraction of the CR4 cells in comparison to the bulk tumor cells, we have identified about 360 differentially
expressed transcripts, many of which represent stemness, pluripotency and resistance to treatment. Majority of the
established CR4 cells express common markers of stemness, including CD133, CD44, CD166, EpCAM, CD24 and Lgr5. Using
immunocytochemical, FACS and western blot analyses, we have shown that a significant ratio of the CR4 cells express key
markers of pluripotency markers, including Sox-2, Oct3/4 and c-Myc. Constitutive overactivation of ABC transporters and NF-
kB and absence of tumor suppressors p53 and p21 may partially explain exceptional drug resistance of the CR4 cells.
Conclusions: The highly tumorigenic and clonogenic CIC-enriched CR4 cell line may provide an important new tool to
support the discovery of novel diagnostic and/or prognostic biomarkers as well as the development of more effective
therapeutic strategies.
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Introduction
Colorectal cancer has the third highest incidence and mortality
rate among the US population [1]. The current lack of curative
chemotherapies and the highest attrition rate of anticancer drugs
compared to other diseases (only 5% of agents that have
anticancer activity in preclinical development are licensed; [2])
create an urgent need for more physiologically and clinically
relevant sources of cancer cells, as well as for more relevant in vitro
and in vivo models. Traditional cancer research and preclinical
evaluation of candidate anticancer agents are based on the use of
unselected long-term, high-passage established cancer cell lines
grown as a monolayer cultures. However, long-term in vitro
maintenance inevitably leads to the accumulation of additional
genomic and epigenomic changes, as well as the selection of
dominant cell subpopulations. Indeed, it was recently demonstrat-
ed that the most commonly used established cancer cell lines have
no correlation with original clinical samples [3]. This suggests that
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the use of established cell lines for the study of genomic alterations,
discovery of clinically relevant molecular targets, and anticancer
drug development is questionable, since the use of these cell lines
does not account for the complexity and pathophysiology of in vivo
tumors.
It is largely accepted now that human tumors are organized
hierarchically, and the top of this hierarchy is occupied by
malignant stem cells, which possess unlimited self-renewal and
tumor--initiating capacities. According to the most recent concept
of carcinogenesis, which has revolutionized the understanding of
tumorigenesis and cancer treatment, only specific phenotypic
subpopulation(s) of cancer stem cells (CICs) or cancer-initiating
cells (CICs) are responsible for tumor development, production of
the entire spectrum of the differentiated progeny that compose a
tumor mass, metastasis, and resistance to anti-cancer therapies [4–
6]. Such cells were recently isolated from all major human cancer
types, including colorectal cancers [7–9]. Numerous studies have
demonstrated that specific phenotypes of stem-like tumor-initiating
cancer cells are highly drug resistant and are capable of self-
renewal after standard therapeutic interventions [10–17]. All of
the above considerations highlight the crucial role of CICs in the
discovery of clinically relevant molecular targets and anticancer
drug development.
The identification and characterization of patient-derived CICs,
the development of optimal in vivo and in vitro preclinical models,
and CIC-targeted analyses of drug-induced alterations represent
critical steps in the assessment of novel anti-cancer therapies. It is
evident also that in order to maintain suitable fidelity to the
original tumors, the cancer-initiating cells (CICs), as well as other
cell types used for genomic and proteomic profiling, should be
isolated from a large spectrum of primary and metastatic tumors,
not from the established cancer cell lines. However, it is
notoriously difficult to establish primary cell lines and particularly
CIC lines from fresh tumor specimens [18]. First, there are
objective difficulties in the isolation of pure cell populations from
heterogeneous tumor tissues. Tumor impurity (different levels of
non-tumor cell contamination) and multiclonality are well-
documented problems [19,20]. At the molecular level, there are
currently no definitive markers to prove the malignant or
nonmalignant nature of cells, as well as to accurately distinguish
between normal and cancer stem cells. Growing evidence also
suggests that CICs might represent a heterogeneous subpopulation
of the tumor-initiating cells [21–25]. Nevertheless, a combination
of multiple approaches and multiple cell surface markers followed
by a thorough functional characterization of the isolated cell
phenotypes may enable the purification of the most functionally
significant, i.e. tumor-and metastasis-initiating and the most drug-
resistant cells. Several colorectal cell lines of different cellular,
biochemical and molecular characteristics have been established
during the last two decades [26–30]. Here we report the
establishment of a novel CIC-enriched, highly tumorigenic
colorectal cancer cell line isolated from liver metastasis of a
CRC patient.
Results
Patient specimens and primary cultures
Dissociated cell suspensions from 13 freshly resected colorectal
carcinomas of various histological grades and 3 liver metastases
were tested for clonogenic and tumorigenic potential in vivo and in
vitro as described in the Methods section. Two specimens were
severely contaminated with bacteria, and despite repeated
treatments with antibiotics, the primary colonies were also
contaminated and therefore discarded. Two primary cultures
developed from primary and metastatic tumor specimens of
patients previously treated with chemotherapy underwent pro-
found cell death after 1–2 days in culture and did not show any
viable cells during the next week of observation. The other nine
specimens contained a subpopulation of fast-adherent cells (FA) to
the type I collagen, which initially proliferated in serum-free stem
cell medium and induced floating spheroids, which are charac-
teristic of CICs, as well as loose multicellular aggregates in 3D
cultures. However, 6 of 9 primary cultures lost their clonogenic
and sphere-forming capacities after several passages, which is in
line with numerous observations that primary cancer cells have a
finite (about 5–6 passages) lifespan [31]. In contrast, tumor cells
isolated from the liver metastasis of the male patient with stage 4
colon cancer continue long-term in vivo and in vitro growth (15
passages, currently) and represent an established, CIC-enriched
colon cancer cell line, CR4. Three other primary cultures are
currently undergoing evolution similar to the CR4 cell line. These
cells are in the process of functional, genomic, cellular and
molecular characterization.
Cellular and clonal heterogeneity of CR4 tumor cells
After initial isolation of the fast adherent to type I collagen
primary tumor cells and their propagation in vitro in MSCB or SPC
media, several different types of cell shape and clone morphology
were evident: (i) densely packed long spindle-like cells representing
carcinoma associated fibroblasts (CAFs) and normal fibroblasts,
which were dominant cell phenotype soon after isolation and
during several early passages of culturing (Figure 1A); (ii) sparse
large elongated cells with dychotomized processes (Figure 1B); (iii)
rare small clones containing small round cells about 7–10 mm in
diameter with a very thin rim of the cytoplasm and large elongated
nuclei (Figure 1C, D); and among them, (iv) rare, very large ($
100–200 mm), often multinucleated cells (MNCs; Figure 1E). We
often observe such cells in both established and primary colon and
prostate cancer cell lines grown under stemness-promoting
conditions. These multinucleated giant cells were capable of both
slow proliferation, producing either additional MNCs (Figure 1F)
or large mononuclear cells.
We have continued culture of the mixed cell populations under
defined stemness-promoting conditions expecting that this ap-
proach, similarly to our previously established primary prostate
CIC-enriched cell line, PPT2 [32] will lead to the propagation of
the rare CICs. In line with our observations, it was shown earlier
that co-culture of the colon cancer cells with carcinoma-associated
fibroblasts led to anincrease in the number of CICs via activation
of the b-catenin pathway [33]. Finally, limited passaging of
primary cells in a stem cell media led to the appearance of
numerous sparse, small cell-containing, densely packed clones with
smooth edges (holoclones) surrounded by elongated cells
(Figure 2A). This pattern is characteristic for embryonic, induced
pluripotent and other stem cell types co-cultured with fibroblasts
[32,34]. Sucloning of such holoclones led to the establishment of
the purified colon cancer cell line, CR4, with all the basic features
of CICs, including high tumor-initiating, 3D spheroid-and
holoclone-forming capacities and expression of the pluripotency
and stem cell-relevant markers (described below). Along with the
putative smooth-edged holoclones, CR4 cells can induce para-
clones with diffuse edges (Figure 2C), which are characteristic for
progenitor cells. During the earlier passages, almost all CR4
holoclones contained uniformly packed small cells from the center
to periphery of the clone (Figure 2B). However, later passages had
much higher ratios of the large multinucleated cells located
predominantly at the periphery of the clone, whereas small cells
occupied the more central part of the clone (Figure 2 E, F). The
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ultra-low passages of the CR4 cells are kept in aliquotes in liquid
nitrogen; currently, this line is at passage 14. For the described
characterization, the frozen aliquotes were propagated either as
NOD/SCID mice tumor xenografts, floating 3D spheroids or type
I collagen-adherent cultures.
Functional characterization of CR4 cells
To confirm the stemness state of the CR4 cell line, several
functional assays were carried out including evaluation of the
tumor-initiating potential (ability to form subcutaneous tumors in
immunodeficient NOD/SCID mice), sphere-forming capacity
(ability to form dense floating spheroids in nonadherent 3D
cultures) and clonogenicity (ability to form adherent to type I
collagen holoclones). We have determined that the CR4 cells
possess high efficiency in induction of tumors in NOD/SCID mice
(Figure 3A) after serial subcutaneous transplantations of the
relatively low cell number. Thus, 16103 CR4 cells or 2–3 floating
spheroids induced large tumors in all mice (6 mice per each
group). To establish clonogenic and sphere-forming capacities of
the CR4 cells, a known number of cells were seeded on type I
collagen-coated or ultra-low adherent plates, respectively. After
one week of incubation, induced adherent clones or floating
spheroids were counted and the clonogenic efficiency was
calculated as the ratio of the number of seeded cells compared
to the number of induced colonies or spheroids. In particular, we
determined that after seeding unsorted CR4 cells of passage 13 in
serial dilution (250, 100, 50 and 25 cells/well of 96-well plates)
about one cell in 10 (10%) induced perfect holoclones (Figure 2B,
D). Sphere-forming efficiency of the CD133-positive fraction of
the CR4 cells in 3D culture with 5% type I collagen in SPCM was
higher compared to the CD133-depleted cell populations (8.462.6
versus 3.760.6 spheroids per 100 seeded cells/well, respectively).
Both holoclones and spheroids were packed with very small cells
expressing high levels of common stemness markers, including
EpCAM, CD133, CD44, CD166 and Lgr5 (described below).
Although the CD133 (clone 293C3), as well as any other common
markers, is not ideal for colon CICs, nevertheless it allows for
additional enrichment of the tumor-initiating and sphere-forming
fraction of the CR4 cells.
The aggressive nature and exceptional sphere-forming/clono-
genic capacity of CR4 cells were demonstrated by their ability to
produce floating spheroids not only in non-adherent cultures
(Figure 3B), but also by budding of the adherent to type I collagen
holoclones and consequent detachment of the formed spheroids
(Figure 3C). The CR4 holoclones were also able to produce the
large adherent multilayer organoids directly above the holoclone
surface (Figure 3D). Floating CR4 spheroids behaved differently in
3D culture systems with and without type I collagen gels in stem
cell media (MSCBM or SPCM). Thus, spheroids grown with no or
low percent of collagen gel (up to 5%) usually have smooth edges
(Figure 3B), whereas higher gel concentration (up to 10–15%) led
to the appearance of multiple processes, which formed asterisk-like
structures surrounding spheroids (Figure 3E). Such phenotype of
floating spheroids was recently associated with high metastatic
capacity of particular cancer cells [35], which is in line with the
fact that the CR4 cell line was established from liver metastasis of
the colon cancer patient. Similarly to 3D culture, the invasive
nature of the CR4 cells was reflected by their ability to develop
long, large, dichotomized processes on the outer edge of the
adherent clones (Figure 3F). The large multinucleated cells on the
periphery of the clones, described above, as well as single gigantic
multinucleated cells, also often displayed long and dychotomized
processes (Figure 3G).
Phenotypic profiling of CR4 cells
As we mentioned above, subcloning of the small-cell-containing
holoclones led to dramatic enrichment of cells expressing high
levels of stemness and pluripotency markers (Table 1; Figures 4
and 5). In general, stem cell phenotype in vitro is dynamic due to
the dual nature of CICs (i.e., their ability to self-renew and to
generate committed progenitors). Thus, early and intermediate
passages of primary CR4 cells had unstable phenotype expressing
highly variable levels of CD133, CD44 and EpCAM (Table 1 and
Figure 4A). The NOD/SCID mice tumor xenografts induced by
these cells expressed similar levels of all studied markers
(Figure 4B). In contrast, purified CR4 cells retain relatively stable
phenotype in 3D and adherent to the type I collagen cultures.
Thus, three independent FACS analyses during the last 7 months
(passages 6–14) have shown that virtually the entire population of
Figure 1. Cellular heterogeneity of the CR4 tumor cells. (A) Initially dominating population of the densely packed elongated fibroblast-like
cells. (B) Sparser elongated tumor cells with processes. (C) Appearance of small clusters of very small cells (,7 mm) adjacent to fibroblast-like cells.
(D) Typical holoclone induced by small CR4 cells. (E) Giant multinucleated cell within CR4 holoclone of small cells. (F) Colony of multinucleated cells.
doi:10.1371/journal.pone.0099091.g001
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CR4 cells remains undifferentiated (only 3–5% expressed marker
of differentiation, pan-keratin), and the majority of cells express
high levels of CD133 (62–82%), CD44 (65–99%), CD166 (97–
98%), EpCAM (98–99%) and Lgr5 (80–83%; representative
FACS data are shown on Figure 4C). In particular, about 65%
of cells coexpressed high levels of CD133 and CD44. Importantly,
about 20% of CR4 cells are positive for marker of metastatic
activity, CXCR4.
Using immunocytochemical, FACS and western blot analyses,
we have shown that a significant ratio of the CR4 cells express
several key markers of pluripotency, including Sox-2, Oct3/4 and
c-Myc. Nuclear localization of these markers shown by ICC
(Figure 5A, B) was confirmed by western blotting (C), which has
demonstrated their expression in the nuclear protein fraction and
their absence in the cytoplasmic one. We have found that the
CD133+ fraction of the CR4 cells express higher ratios of several
markers of pluripotency compared to the unsorted CR4 cells.
Thus, FACS analysis has shown that more than a quarter of the
CD133+ population expressed Sox-2 and 10% of the population
were positive for c-Myc (Figure 5D). In contrast, unsorted CR4
cells and CD133-negative fraction expressed lower levels of these
pluripotency markers (6 and 4%, and 1.4 and 0.8%, respectively;
Figure 2. Subcloning of the small CR4 cells. (A) Clone of small CR4 cells surrounded by long fibroblast-like cells with dychotomized processes.
(B) After subcloning, small CR4 cells seeded at low density in serum-free SPCM on type I collagen produced typical densely packed holoclones
characteristic for stem cells of different origin. (C) Paraclone of elongated larger cells adjacent to small CR4 cells. (D) Low number of the purified small
cells produced predominantly round-edged holoclones and rare paraclones adherent to type I collagen with high efficiency. (E) Higher magnification
of the holoclone cells with large nuclei and thin rim of cytoplasm. (F) Large MNCs ($200 mm; hematoxylin and eosin staining) are often located at the
periphery of the holoclones.
doi:10.1371/journal.pone.0099091.g002
Figure 3. Functional characterization of the CR4 cells. (A) Large subcutaneous tumor induced by transplantation of the CR4 cells (16103) in
NOD/SCID mouse (passage 2). (B) Dense floating spheroids induced by serial passaging of the CR4 cells in 3D culture on the ultra-low-adherent
plates. (C) Three-dimensional spheroid induced on the surface of the adherent CR4 holoclone. (D) Formation of a large 3D organoid on the surface of
the adherent CR4 holoclone. (E) Appearance of long processes in spheroid cells induced by CR4 cells in 3D culture containing 15% of collagen gel,
which indicates their high invasive potential [35]. (F) Long dychotomized processes developed by adherent small CR4 cells. (G) Long processes of
adherent MNCs.
doi:10.1371/journal.pone.0099091.g003
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Figure 5E; negative fraction is not shown). Colocalization analysis
has shown that only cells with the highest expression of CD133
usually have nuclear staining for the pluripotancy markers
(Figure 5B; only c-Myc is shown). High proportion of the Sox-2-
positive cells and its nuclear localization was also confirmed by
IHC of the NOD/SCID mice tumor xenografts (Figure 5F). [Of
note, the use of the anti-Oct3/4 (Santa Cruz Biotechnology, CA,
USA) for FACS analysis provided suspiciously high ratios of
positive cells (more than 90%) and these data were not included.]
Importantly, the CR4 cells, similarly to the prostate PPT2 CIC-
enriched cell line [32], did not express the two major regulators of
apoptosis and tumor suppressor genes, p53 and p21 (Figure 5C).
In addition, the nuclear fraction of the CR4 cells grown on type I
collagen in stem cell medium as separate holoclones strongly
expressed phosphorylated p65, which means that NFkB is
constitutively overexpressed in colorectal CICs. In contrast,
unphosphorylated p65 was located predominantly in the cytoplas-
mic fraction. All of the above may partially explain the high
tumorigenic and clonogenic capacities and exceptional drug
resistance of this CIC-enriched cell line. In particular, CR4 cells
are highly tolerant to treatment with commonly used cytotoxic
drugs such as Paclitaxel or Taxol (Figure 6). Thus, after 72-hour
treatment in concentration range from 10 nM up to 10 mM (MTT
assay), CR4 cells have shown little or no cytotoxicity; moreover,
they often increased their proliferation in response to lower doses
of the paclitaxel. We have found that several members of new-
generation taxoids, including SBT-1214, SBT-121602 and SBT-
12834 are more effective against CR4 tumor-initiating cells. The
IC50 death rate was reached at $10 mM of all drugs concentra-
tion. Of note, the promising efficacy of low concentrations of new-
generation taxoids can be further improved by their combination
with the synthetic derivative of curcumin, CMC2.24 (unpublished
data), which is line with our previous study [32].
Histopathological and IHC analyses of the NOD/SCID
mice tumor xenografts
As we mentioned above, subcutaneous transplantation of a
relatively low number of CR4 cells (16103 of the dissociated CR4
cells or 2–3 floating spheroids) induced large vascularized tumors
in all injected NOD/SCID mice (Figures 3A and 7A). The
hematoxylin-and eosin-stained tissue sections of the mice tumor
xenografts showed classic histologic features of human metastatic
colon cancer (Figure 7B, C). Highly atypical epithelial cells formed
villous-like structures with prominent elongated nuclei and,
consistent with poorly differentiated adenocarcinoma, numerous
atypical mitotic figures. Central necrosis was usually present.
Numerous large multinucleated cells were evident at higher
magnification (Figure 7C; arrows). Immunohistochemical analysis
revealed that entire tumor area (but not tumor stroma) expressed
high levels of the membrane-localized EpCAM (Figure 7D, E).
Figure 4. Molecular characterization of the CR4 cell line: expression of cell surface markers. (A) Representative FACS analyses of the
different cell surface markers expression in early primary culture of the fast-adherent CR4 cells grown on type I collagen in MSCB medium. (B) FACS
analysis of the first passage of FA tumor cells isolated from NOD/SCID mice tumor xenografts induced by early-passage CR4 cells. (C) Dramatic
increase in the expression of the common markers of stemness, including CD133, CD44, CD166, Lgr5 and EpCAM in the late-passage (p13) CR4 cells.
Note that 19% of cells also expressed marker of CICs with metastatic activity, CXCR4, which was identified in multiple human cancers.
doi:10.1371/journal.pone.0099091.g004
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Similar patterns and levels of expression were characteristic for
CD166 (F). In contrast, immunostaining with polyclonal CD44
(clone F10-44-2; Invitrogen/Biosources, USA) revealed three
different patterns of expression in different areas of the same
tumor, i.e. clearly membrane (Figure 7G), as well as cytoplasmic
and clearly nuclear in other parts (Figure 7H). High cytolasmic
expression of the common marker of colon stem cells and CICs,
Lgr5, was evident in some tumor parts (Figure 7J), whereas in
other parts, it was either moderately or weakly expressed (K), or
even absent. Large areas of the tumor xenografts expressed strong
nuclear staining for the pluripotency marker Sox-2 (Figure 7L).
RNA-Seq complete transcriptome profiling of CR4 small
versus bulk tumor cells
Using RNA-Seq, we performed a functional genomic analysis in
tumor-initiating fractions of CR4 (small) cells grown adherent to
type I collagen versus grown as 3D spheroids, in comparison to the
bulk tumor cells (long and dychotomized cells grown under
standard culture conditions). Using a HiSeq 2000, we sequenced
between 40 and 50 million reads per biological sample, as
previously described [35,36,37]. Briefly, libraries for NGS were
made from 100 nanograms of total RNA. The RNA samples
quality was assessed with an Agilent Bioanalyzer. All RNA samples
had a RIN above 8. Sequencing libraries were created using the
Illumina TruSeq Stranded mRNA LT kit according to manufac-
turer recommendations. The quality of each library was evaluated
with the Agilent bioanalyzer high sensitivity assay, and quantified
by qPCR (Kappa Biosystem, CT). The libraries were pooled
together at 10 nM based on the qPCR results, and then the pool
was quantified again by qPCR. The pooled library was sequenced
in one lane of a HiSeq2000 paired end 100bp flow cell. This
allowed us to detect which transcripts are differentially expressed
among these types of CR4 cells, thus building a comprehensive
picture of the activated or repressed signaling pathways. We have
Figure 5. Expression of key pluripotency markers in CR4 cells. (A) Nuclear localization of key pluripotency markers, c-Myc, Sox-2 and Oct3/4.
(B) Co-localization of nuclear c-Myc with high membrane expression of CD133. (A, B: Immunocytochemical analysis of CR4 cells grown on type I
collagen-coated chambered slides). (C) Western blot analysis confirms expression of c-Myc and Oct-3/4 in nuclear fractions of the CR4 cells. In
contrast, they are negative for p53 and p21. Nuclear fraction also expressed higher levels of the phosphorilated p65 (which indicate constitutive
activation of NF-kB), whereas unphosphorilated p65 was located predominantly in a cytoplasm. (D, E) Representative FACS analyses show higher
expression of Sox-2 and c-Myc in CD133-positive cells compared to unsorted cells. (F) Immunohistochemical analysis shows high nuclear expression
of Sox-2 in the CR4-induced NOD/SCID mice tumor xenograft. (G) Negative control (tissue section without incubation with primary anti-Sox-2 Abs).
doi:10.1371/journal.pone.0099091.g005
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found that small CR4 cells grown either as separate holoclones
adherent to type I collagen or as 3D floating spheroids possess a
large number of differentially expressed genes in comparison to the
bulk tumor cells grown under standard culture conditions. Thus,
in adherent small CR4 cells and 3D spheroids, 357 and 365 genes,
respectively, were overexpressed compared to the CR4 long (bulk)
tumor cells. Among these genes, 287 were commonly upregulated,
which means that both culture conditions allow for maintenance of
the CR4 small cells at stemness state. In particular, both small
adherent and 3D spheroids expressed up to several orders of
magnitude of upregulation in the following: (i) multiple common
markers of stemness, including CD44, CD24, EpCAM, ESA,
Table 1. Phenotypic evolution of the CR4 tumor cells (FACS analysis).
Early Primary cultures (% of positive cells) Intermediate (% of positive cells) Established CR4 (% of positive cells)
Marker Adherent* 1st xenograft** Adherent Adherent***
EpCAM 3.461.6 6563 8465 9762.7
CD133 1.561 2.260.6 1565.5 6269.7
CD44 7.560.5 761 35613 82617.3
CD166 7065 9761
CXCR4 160.5 1.2604 2062.2 82617.3
Lgr5 81.560.5 8362
CXCR4 10.561 1962
Sox-2 360.5 2061.5
c-Myc 160.2 1062.8
* Early passages (# 2–4) of the fast-adherent to type I collagen CR4 cells isolated from patient tumor.
** Fast-adherent cells isolated from the first passage of NOD/SCID mice tumor induced by early passage.
CR4 cells.
*** Late passage of CR4 cells, which were twice transplanted to NOD/SCID mice and grown under.
stemness-promoting conditions (passages 11–13).
Note: Data from at least three different FACS analyses were expressed as means 6 SD for each marker.
Initially very low cell number didn’t allow more complete evaluation of the stemness/pluripotency markers.
doi:10.1371/journal.pone.0099091.t001
Figure 6. CR4 cells are highly resistant to treatment with cytotoxic drugs (comparative cytotoxicity of paclitaxel and new-
generation taxoids against CR4 cells). Commonly used Paclitaxel (Taxol) in doses lower than 10 mM is not effective against CR4 cells and often
increases their proliferation. In contrast, several new-generation taxoids induce dose-dependent inhibition of proliferation of these potent tumor-
initiating cells. (MTT assay after drug treatment for 48 hr). The obtained p values for all the drugs and all the drug concentrations were much smaller
that 0.05. The largest p value was obtained for SBT-1214 at 10 nM concentration (p= 0.0131); in particular, at 10 mM concentration of SBT-1214
p= 0.00032.
doi:10.1371/journal.pone.0099091.g006
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Lgr5, ALDH1A1 and others; (ii) growth factors, including the
epidermal (EGF), fibroblast (FGF) and transforming growth factor-
beta (TGFb) family members; (iii) transcription factors (TFs),
including multiple homeobox (CDX1, CDX2, CEACAM6,
MSX2) and pluripotency TFs (POU5F1B, Oct4, Sox-2, Sox-9;
(iv) inflammatory cytokines and their receptors, including IL18,
IL20, IL2RG, IL20RA and others; (v) ABC transporters; (vi) genes
responsible for transfer of high energy phosphate from mitochon-
dria (CKMT1 and CKMT1B) and the members of cytochrom
P450 family, including CYP2B6, CYP2J2, CYP2S1 and others. Of
interest, the tumor-initiating fraction of the CR4 cells overex-
pressed multiple genes controlling cell-to-cell adhesion, including
cadherins (CDH 1, 3 and 17, and CDHR5); intergins (ITGB4);
genes encoding tight-junction proteins (CLDN3, 4 and 6,
COL17A1 and others); and keratins (KRT19, 20, 23 and
KRTAP3-1). This finding supports our traditionally used
approach for initial enrichment of the prostate and colon tumor-
initiating cells based on their ability to adhere to type I collagen-
coated surfaces within 15–20 minutes of incubation. The obtained
raw RNA-Seq data were submitted to the National Center for
Biotechnology Information (NCBI) Gene Expression Omnibus
(GEO), a public functional genomics data repository (the ID
number is GSE56660).
STR profiling of the original tumor and isolated CR4 cells
Both the parental tumor tissue and the isolated tumor-initiating
population of this tumor (xenograft CR4 cells) were subjected to
the short tandem repeat (STR) profiling by the GRCF at John
Hopkins DNA Services/FAF. STR profiling by the GRCF is
carried out following the ANSI/ATCC ASN-0002-2011, Authen-
tication of Human Cell Lines: Standardization of STR Profiling.
According to this report, both samples represented unique human
Figure 7. Histopathological and immunohistocheminal analyses of the CR4-induced mice tumor xenograft tissues. (A) Large tumor
induced by transplantation of 16103 CR4 cells. (B) Hematoxylin -and eosin-stained tissue section shows classic histologic features of human
metastatic colon cancer. (C) High power magnification of region shown in (B); arrows show giant multinucleated cells within the papillary structures.
(D, E) Strong cell surface expression of the epithelial marker, EpCAM. (F) Strong cell surface expression of CD166. (G) Cytoplasmic expression of CD44.
(H) Microscopic focus with strong nuclear and weaker cytoplasmic expression of CD44. (I) Negative control (primary Abs were omitted). (J, K) Strong
and moderate expression, respectively, of the colon stem cell marker, Lgr5/GPR49. (L) Strong nuclear expression of the pluripotency marker, Sox-2 in
large areas of the tumor.
doi:10.1371/journal.pone.0099091.g007
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profiles, which do not match any profile in either ATCC
(American Tissue Culture Collection) or JCRB (Japanese Collec-
tion of Research Bioresources). The STR profiles of the parental
tumor and the established cell line after xenografting in NOD/
SCID mice are identical with the exception of the loss of the Y-
chromosome in CR4 cells, which is a common phenomenon for
different types of human malignancies. Thus, the Y-chromosome
loss was reported in 20 out of 26 karyograms of CIC-enriched
highly tumorigenic pancreatic cell line [34].
Discussion
It is largely accepted now that effective anticancer therapies
should be focused not only on the bulk mass of the tumor, but
most importantly, on functionally significant cells possessing high
tumor-initiating capacity and high resistance to treatment, i.e.
CICs. It is also well established that human tumors are highly
heterogeneous both intra-and interindividually. Given the fact that
the majority of established long-term passaged cancer cell lines do
not reflect either complexity, or individual features of the parental
tumors [3,38], it is conceivable that modern cancer research and
anti-cancer drug development should be based on novel in vitro and
in vivo systems allowing for physiologically and clinically more
relevant modeling and more objective evaluation of drug efficacy.
Molecular, biochemical, genomic and proteomic characterization
of human tumors aims to discover novel targets that potentially
can cure cancer. But in reality, clinically and physiologically
relevant targets are covered by noise from the dominating cell
populations in unselected, bulk tumor masses, often contaminated
with different levels of non-tumor cells, including normal
fibroblasts and CAFs, endothelial cells, pericytes, inflammatory
and other cells. Therefore, the selection of clinically and
physiologically appropriate molecular targets should be funda-
mentally based on the selection of appropriate, clinically and
physiologically significant cells, even if they represent a very minor
population within the individual tumor. Secondly, profound intra-
and inter-individual variations in grade of differentiation,
morphology, level and type of chromosomal abnormalities, as
well as the ratio of tumor-and metastasis-initiating cells require the
availability of a large spectrum of patient-derived low-passage cell
lines. Moreover, such primary cell lines should preferably be
established from multiple tumor foci in order to better reflect
intratumoral complexity, heterogeneity and hierarchy. As we
mentioned above, the establishment of patient-derived low-
passage cancer cell lines from fresh tumors in vitro remains
technically difficult [18–20,27,31,39,40]. In part, this is due to the
natural heterogeneity and multiclonality of human cancers, which
makes it difficult to isolate the most clinically significant malignant
clone(s) given the limited size and number of fresh tumor
specimens. In addition, the frequent incompatibility of research
needs (availability of fresh, promptly microdissected malignant
specimens) and routine clinical processing of resected tumors
(usually delayed pathological evaluation and their preferential
storage in fixatives) further complicates this situation. Even more
difficult is the establishment of purified CIC lines due to the rarity
of these cells within the tumor and their often unpredictable
behavior in vitro. However, although the commercially available
established cancer cell lines are very convenient, user-and budget-
friendly, and have for many decades remained to be a major
resource for cancer research and anti-cancer drug development,
several serious concerns were recently raised. While established
cancer cell lines do contain different ratios of clonogenic and
tumor-initiating cells, the long-term maintenance of these lines
inevitably leads to dramatic deviation of their features from those
of parental tumors. Thus, a recent NIH-based study has
demonstrated that the most commonly used collection of the
established cancer cell lines, NCI-60, has no correlation with the
original clinical specimens [3]. Here we report the establishment of
the colon CR4 cell line, which is highly enriched with tumor-
initiating and holoclones-and 3D spheroid-forming cells with stem
cell properties. Under described conditions, the vast majority of
the fast adherent to type I collagen tumor cells initially grew in
both 3D and adherent culture systems (in contrast to a previous
study [27] that found that only 3 of 31 tumor specimens grew
initiallyin vitro). However, these cells usually lost their clonogenic
capacity after several passages. In contrast to all previously studied
commercial cell lines, but similarly to our recently established
purified prostate cancer stem cell line, PPT2 [32], CR4 cells
produced perfect floating spheroids not only in 3D culture, but
also on the surface of the type I collagen-adherent holoclones,
which reflect their exceptional clonogenic/sphere-forming poten-
tial. There is a large body of evidence that 3D tumor cell cultures
more accurately reflect the complex in vivo microenvironment than
the commonly used two-dimensional cell monolayers [35,41]. It
was also shown that human colorectal cancer cells grown on type I
collagen in serum-free medium undergo an epithelial-mesenchy-
mal-like transition [42]. On the other hand, EMT was shown to
generate stem-like cells [43]. In particular, collagen type I
inhibited cell differentiation, increased clonogenicity and promot-
ed expression of CD133 and Bmi1, indicating that it promoted
expression of a stem cell-like phenotype in colon cancer cells [42].
In this context, culturing the adherent to a type I collagen CIC-
enriched cell population in a serum-free stem cell medium can
provide a useful tool for enrichment and maintenance of the
tumor-initiating fraction of cancer cells. Although the morpholog-
ical manifestation of CICs has not been thoroughly investigated,
partly because of the rarity of these cells and a lack of highly
specific markers, accumulating data demonstrate that giant
multinucleated cells, which are present in relatively low numbers
in malignant tissues and cell lines, and can be enriched after
treatment with standard anti-cancer drugs [44,45], possibly
represent a subpopulation of cancer stem cells [46].
Recently, the establishment of a highly tumorigenic CIC-
enriched pancreatic cancer cell line, JoPaca-1, has been reported
[34]. Authors have found a significant decrease in the ratio of cells
expressing CD133, ALDH and co-expressing CD44/CD24/ESA
after 13 consequent passages (80% of the CD133+, 47% of CD44/
CD24/ESA-positive cells and 28% of ALDH+ cells at passage 6
versus 34%, 3% and 10% at passage 19, respectively). In contrast
to JoPaca-1, the ratio of the CR4 cells expressing stemness markers
was significantly increased followed by passaging under defined
stemness promoting conditions. Since this phenotype remained
stable during the last 7 months, we can suggest that CR4 cells
represent purified immature CICs, which are predominantly self-
renewing under described conditions. As we have shown, the
majority of the established CR4 cells, as well as a significant
proportion of cells from NOD/SCID mice tumor xenografts
induced by these cells, express high levels of CD133, CD44,
CD166, EpCAM and Lgr5. We observed widespread membrane,
cytoplasmic and nuclear expression of CD44 after immunostaining
with polyclonal Abs, which may reflect complex functional roles of
this marker. Thus, it is implicated in a wide variety of physiological
and pathological processes as a cell surface adhesion molecule that
interacts with hyaluronic acid, the most abundant stromal
component. In particular, this cell surface hyaluronan receptor
may promote tumor growth and metastasis serving as an anchor
for matalloproteinase MMP9 [47]. In addition, sequential
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proteolitic cleavages of CD44 in the ectodomain and intramem-
branous domain lead to the release of a CD44 intracellular
domain fragment, which acts as a signal transduction molecule
after translocation to the nucleus [48]. About 20% of CR4 cells are
positive for marker of metastatic activity, CXCR4, which is in
agreement with their origin from liver metastasis. The CXCR4,
cell surface receptor for the chemokine CXCL12 (SDF-1), plays a
central role in cancer cell proliferation, invasion, and dissemina-
tion in the majority of malignant diseases. Accumulating evidence
suggests a key role of the CXCL12/CXCR4 axis in the metastatic
niche signaling that regulate CICs [49–53]. In line with recent
studies [54,55], we observed Lgr5-positive clusters of cells with
strong and moderate cytoplasmic staining in poorly differentiated
mice tumors. In contrast to the previously reported spontaneously
immortalized cancer cell lines [56], which express high levels of
p53 and markers of differentiation, the CR4 line is immature and
negative for p53 and p21. Complex mutual regulation within the
p53/p21 axis and p53-regulated miRNAs contribute to tumor
suppression by controlling the expression of such central processes
as cell cycle progression, EMT, stemness, metabolism, cell survival
and angiogenesis; therefore, aberrations in this network play a
critical role in tumor development [57]. The CR4 cells possess
high nuclear expression of the phosphorilated p65, which means
constitutive activation of the NF-kB in these cell lines. It was
previously shown that in colorectal and gastric cancers, inhibition
of nuclear translocation of p65 is associated with reduced cancer
cell proliferation, induction of apoptosis and tumor shrinkage
[58,59]. NF-kB p65 protein was shown to be expressed in a small
subpopulation of CD133+ prostate cancer cells and overexpressed
in 80–100% of metastatic lesions.
In addition to FACS, ICC, IHC and western blot analyses,
using RNA-Seq, we obtained precise measurement of levels of
transcripts, which are differentially expressed in the tumorigenic
fraction of CR4 cells in comparison to bulk (non-stem) tumor cells
from the same tumor (about 360 genes). Next-generation
sequencing (NGS) provides a unique opportunity to uncover the
genomic status of functionally different cell types. In general,
RNA-Seq provides a far more precise measurement of levels of
transcripts and their isoforms than other methods. Functional
characteristics of many of the differentially expressed genes,
including common markers of stemness and key pluripotency
genes, multiple transcription and growth factors involved in cancer
development and progression, overactivated ABC transporters and
others, clearly confirm the stemness state and high drug resistance
of the CR4 cell line. Of interest, the tumor-initiating fraction of the
CR4 cells overexpressed multiple genes controlling cell-to-cell
adhesion, including cadherins, intergins and tight-junction pro-
teins. This finding supports our traditionally used approach for
initial enrichment of the tumor-initiating cells based on their
ability to adhere to type I collagen-coated surfaces within
15 minutes of incubation. The STR profiling of CR4 tumor
xenografts revealed that, similarly to our recently established
prostate CIC cell line, PPT2 [32], CR4 cells possess the loss of the
Y-chromosome, which is in line with observation that deletion of
the Y-chromosome is associated with the simultaneous inactivation
of tumor suppressor genes [60,61]. In general, the loss of the Y-
chromosome and numerical abnormalities of the X-chromosome
are frequent phenomena observed in different cancer types [62,63]
and most tumors possess at least one form of genomic instability
[64]. The absence of p53 and p21 in CR4 cell line reflects their
extremely high resistance to drug treatment. The p53 transcription
factor regulates multiple biological functions via regulation of the
expression of a wide variety of genes involved in apoptosis, growth
arrest, inhibition of cell cycle progression, differentiation and
accelerated DNA repair.
There has been considerable debate as to whether there are
specific CIC markers. In particular, colorectal CICs have been
initially identified using CD44 or CD133 either alone [7–9], or in
combination with other markers, such as EpCAM, CD166, CD29,
CD24, LGR5 and aldehyde dehydrogenase 1, ALDH1 [65–67].
Accumulating data indicate that tumor-initiating cells in many
cancer types cannot be demarcated solely by the expression of
common cell surface markers [68–70]. Although both CD44 and
CD133 were reported as putative markers for many cancer-
specific CICs, including colorectal cancer, it is still unclear
whether they are of equal functional importance. It was shown
that CD133+ normal stem cells at the base of the adult intestinal
crypts (a stem cell niche) not only generate the entire intestinal
epithelium, but give rise to all the neoplastic cells in mice colon
tumors [71]. The proportion of CD133+ cells in colon cancer
metastases is higher than in primary tumors [72], which reflect the
well-known fact that metastatic lesions are more resistant to
treatment. However, another study has shown that only a
knockdown of CD44, but not CD133, strongly prevented clonal
formation and inhibited tumorigenicity in the mice xenograft
model [73], and that CD44+ is not colocalized with CD133+ cells
within colorectal cancer. Similar results reported by Horst and
colleagues showed that the expression of CD133 correlates with
that of CD166, while both do not correlate with CD44 [74].
However, this data contradicts multiple reports which not only
show colocalization of the CD133 and CD44 in several types of
human cancer [7,44,68,75–77], but also suggest their combined
expression as the best CIC marker [68,71]. Such inconsistency
may be due to the high heterogeneity of clinical specimens, the
comparison of the data obtained on clinical specimens with data
obtained on established cell lines, the diversity of experimental
approaches, and the lack of highly specific CIC markers. A recent
study has demonstrated that, in contrast to the established cancer
cell lines, CD133+ cells in primary colorectal cancer samples
showed a unique genomic aberration profile [20], which
additionally highlights the point that the use of established cancer
cell line is questionable [3,20,78].
In conclusion, our data indicate that the CR4 cells isolated from
liver metastasis of colon cancer patient represent an established
cell line, which possesses classical features of CICs, including high
tumor-initiating, clonogenic and sphere-forming capacities and
exceptional resistance to anti-cancer drugs. All of the above
demonstrates that these cells are a highly valuable tool for CIC
research and anti-cancer drug development.
Methods
Tumor Tissue Specimens, Isolation of Cancer Cells and
Primary Cultures
Ethics Statement. Fresh CR tumor specimens were obtained
from SBU patients with clnically proven CRC via a research
protocol approved by Stony Brook University Committees on
Research Involving Human Subjects (CORIHS; #337148-3).
Informed written consent was obtained on all participants. All
experiments involving the use of animals were carried out in strict
accordance with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes of
Health, via a research protocol that was approved by Stony Brook
University Institutional Animal Care and Use Committee (IACUC
#: 2011-1683 - R1 -11.14.14 – MI).
Immediately following resection, tumors were placed in
standard culture medium with antibiotics and antifungal, and
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transported to the laboratory on ice. Fresh tumors were
mechanically and enzymatically disaggregated into single cell
suspension at sterile conditions. Specimens were first minced into
1–2 mm3 chunks, rinsed with Hank’s balanced salt solution and
then incubated for 1 hour in humidified atmosphere containing
5% CO2 at 37uC in serum-free McCoy medium (GIBCO,
Invitrogen, Carlsbad, CA, USA) containing 200 units/ml Colla-
genases type II and type IV (Sigma-Aldrich), 120 mg/ml penicillin
and 100 mg/ml streptomycin. Cells were further disaggregated by
pipetting and serial filtration through cell dissociation sieves (size
40 and 80 meshes; Sigma-Aldrich). Single cell suspensions were
placed on type-I collagen-coated dishes (Biocoat; Becton Dick-
enson, Bedford, MA) in serum-free Mesenchymal Stem Cell
Growth Medium (MSCGM; Lonza) or Stemline Pluripotent
Culture Medium (SPCM; Sigma-Aldrich). One portion of the fast
adherent (FA) cells, which were attached to type I collagen within
the following 15–20 min was used for generation of floating 3D
spheroids, and another one remained on the type I collagen-
coated dishes for further propagation. The FA-depleted cell
suspensions were resuspended in standard McCoy medium
supplemented with 10% fetal bovine serum (Gibco, USA) and
placed either on regular culture dishes or on the type I collagen-
coated ones. The leftover of the undissociated tumor pieces was
removed from the dissociation sieves and also placed in culture.
The media were changed 2–3 times per week. Penicillin,
streptomycin and TrypLE were obtained from Invitrogen (Grand
Island, NY, USA).
Generation of floating multucellular spheroids and in
vitro clonogenic capacity evaluation
Four-five hunderd cells of particular phenotype were seeded on
each well of the Ultra-Low Attachment (ULA) 6-well plate
(Corning, Lowell, MA) in serum-free MSCB medium (Lonza) or
Stemline Pluripotent Stem Cell Culture media (SPCM; Sigma)
containing 5–15% of type I collagen gel and examined after 1
week of culturing under standard conditions. Fresh medium was
added after one week of culturing, every third day. After initial
culturing during 1–2 weeks on ULA plates, primary spheres were
gently disaggregated by repeated pipetting and transferred into
ULA flasks for further propagation and maintenance. Growing
floating spheroids are usually enriched with tumor-initiating cells
and do not contain contaminating cell types such as fibroblasts,
therefore we used them for further propagation of cancer cells by
serial passaging in vitro, for testing clonogenic capacity of the
candidate cell phenotypes and for induction of human tumor
xenografts in immunodeficient mice. For evaluation of the
clonogenic/sphere-forming capacity, cells were counted with
Cellometer Auto T4 (Nexcelom Bioscience LLC, MA), resus-
pended in 1:4 type I collagen//SPCM or 1:4 Matrigel/MSBM
and known cell numbers were plated on ULA plates. One week
after initiation plates were inspected for floating sphere growth and
compact well-shaped spheroids were counted. Spheroids were
serially passaged by gentle dissociation and mixing with a new type
I collagen/MSCBM or type I collagen/SPCM and reseeded on
ULA plates of flasks for further propagation and analysis. Sphere-
forming efficiency was calculated as a ratio of seeded cells to the
number of produced 3D spheroids.
Adherent to type I collagen cultures
The CD133high/CD44high cells (4–56103 cells/well were seeded
onto the type I collagen-coated 6-well plates, and the experiments
were initiated 24 h later, upon sub-confluency. The regular MSCB
medium was replaced with treatment media containing SB-T-
1214 at selected concentrations (0.001–0.1 mg/ml). Treatment
media was removed 24 hr later, followed by washing with regular
MSCBM and dissociation of cells with an Enzyme-free dissociat-
ing reagent (Chemicon International). Upon termination (48 hr
from start), cell viability and cell death was analyzed through flow
cytometry.
Generation of human tumor xenografts and in vivo
tumorigenicity tests
All experiments involving the use of animals were performed in
accordance with SBU institutional animal welfare guidelines.
NOD/SCID mice (Charles River Laboratories, Wilmington, MA,
USA) were maintained under defined conditions at the SBU
animal facility. Aliquots of the particular cell populations were
counted and cell viability was determined by iconventional trypan
blue test. Cells were resuspended in ice-cold 1:1 mixture of growth
medium and Matrigel Matrix (BD Biosciences) and 40–50 ml were
injected subcutaneously into the flanks of 6–8-week-old mice. The
primary tumor sizes were measured with a caliper on a weekly
basis and approximate tumor weights determined using the
formula 0.5ab2, where b is the smaller of the two perpendicular
diameters. All mice were sacrificed at the first signes of suffering or
if the tumor measured$2 cm. Euthanasia was completed by CO2
inhalation following strict guidelines outlined by the panel on
Euthanasia, American Veterinary Medical Association in SBU
DLAR Facility.
Subclonning and establishment of stable CR cancer cell
lines
Since the ability to induce the round adherent colonies with
smooth adges (holoclones) is associated with stem cells, upon
appearance of such colonies, they were subcloned and propagated
under defined stemness-promoting conditions, i.e. growing on type
I collagen-coated surfaces in serum-free stem cell mediums, with
repeated cell sorting, passaging as a 3D spheroids and NOD/
SCID mice xenografts.
Isolation, purification and characterization of the tumor-
initiating cell phenotypes
To ensure more reliable isolation of CICs, cells were labeled
with one or several common markers of stemness conjugated with
different fluorescent dyes, including anti-human CD133/2-APC
(clone 293C3) and CD133/1-PE (clone AC133; Miltenyi Biotec,
CA, USA); CD166-PE (clone 105902; R&D Systems, MN, USA);
CD44-FITC (clone F10-44-2), CD44-PE (clone F10-44-2; Invitro-
gen/Biosources, USA); CD44v6-FITC (clone 2F10; R&D Sys-
tems, USA), EpCAM-FITC (Biosource, CA, USA), Pan-Keratin
(C11) -Alexa Fluor 488 (Cell Signaling) and all the isotype controls
(Chemicon). Antibodies were diluted in buffer containing 5%
BSA, 1 mM EDTA and 15–20% blocking reagent (Miltenyi
Biotec) to inhibit unspecific binding to non-target cells. After 15
min incubation at 4uC, stained cells were sorted and analyzed with
multiparametric flow cytometer BD FACSAria (Becton Dickinson,
CA). Alternatively, dissociated cells were centrifuged at 950 g for 5
min at 4uC, rinsed with sterile MACS buffer (Miltenyi Biotec, CA)
and labeled with CD133 Abs directly or indirectly conjugated with
ferromagnetic beads (Miltenyi Biotec, CA) as recommended by
manufacturer.
Immunocytochemical analysis of the pluripotency
markers expression
For staining with OCT-4, Sox-2 and c-Myc, cells were fixed and
permeabilized with Cytofix-Cytoperm kit (BD Pharmingen, San
Diego, Ca, USA) according to the manufacturer’s instructions.
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Cells were then incubated with monoclonal mouse IgG2b anti-
human OCT-3/4, Sox-2 and c-Myc (Santa Cruz Biotechnology,
Santa Cruz, Ca, USA) at 4uC for 30 minutes, washed twice with
PBS and incubated with corresponding secondary Abs [phycoer-
ythrin (PE)-conjugated polyclonal goat anti-mouse] at 4uC for
30 minutes. hEpCAM-FITC (Biosource, CA, USA), biotin-conju-
gated anti-human CD133 as primary Abs (Miltenyi Biotec, CA,
USA) and streptavidin-FITC (BD Pharmingen, USA) as a
secondary Abs were used.
RNA-Seq
Libraries for NGS were generated using 1 microgram of total
RNA. The RNA quality was assessed with an Agilent Bioanalyzer.
All RNA samples had a RIN above 8. Sequencing libraries were
generated using the Illumina TruSeq Stranded mRNA LT kit
according to manufacturer recommendations. The quality of each
library was evaluated with the Agilent bioanalyzer high sensitivity
assay, and quantified by qPCR (Kappa Biosystem, CT). The
libraries were pooled together based on the qPCR results, and
then the pool was quantified again by qPCR. The pooled library
was sequenced in one lane of a HiSeq2000 paired end 100bp flow
cell. The Illumina HiSeq 2000 uses the sequencing-by-synthesis
process, whereby in each cycle a single fluorescently tagged
nucleotide is added to the clustered DNA templates, after which
high-resolution images are taken to identify the nucleotide added.
The added nucleotides are chemically modified so that they can
accept another round of nucleotide addition, and the cycle is
repeated. The HiSeq 2000 produces 100 bp sequences from one
end of the DNA templates (single-end sequencing), and provides
the option for generating additional sequence from the same
templates from the other end (paired-end sequencing. Image
processing and basecalling were performed as the runs progressed
with Illumina’s Real Time Analysis (RTA) software. The binary
basecall files were streamed to a shared Linux server for further
processing. The Illumina Casava pipeline (v1.8.2) was used to
convert the binary files to fastq files containing the basecalled reads
and per base quality scores. Only reads passing the standard
Illumina quality filter were included in the output files. Casava was
also used to de-multiplex reads into individual files for each
barcode, allowing 1 mismatch in each barcode sequence.
Western blotting
Nuclear extracts were prepared using Active Motif Nuclear Co-
IP kit (Active Motif, Carlsbad, CA) according to manufacturer’s
protocol. The protein content was determined using BCA method
and extract were suspended in Laemmli buffer at final concen-
tration of 0.5 mg/ml. Cell pellets were suspended in Lysis Buffer
(Active Motif, CA) and incubated for 10 min on ice on a rocking
platform. After brief vortexing, cell lysates were centrifuged at
4,000 g for 30 min at 4uC. The protein content in the supernatant
was determined by a Bradford method, and equivalent amounts of
total proteins (10 mg) were resolved on 10% SDS-PAGE gel. After
transferring to a polyvinylidene fluoride membrane, levels of
various proteins were determined by Western blot analysis using
antibodies specific for Oct4, Sox2, Nanog, Lin-28, c-Myc,
GAPDH and b-actin, respectively (1:500 dilution, 4uC, overnight).
Following incubation with peroxidase-conjugated secondary Abs
(anti-rabbit IgG; ECL, UK) for 1 hr at 25uC, blots were developed
using the enhanced chemiluminesens (ECL) reagents. Alternative-
ly, the blots were washed three times with PBST and incubated
with AlexaFluor 680-conjugated goat anti-rabbit secondary
antibody (Invitrogen) for 1 hr. Blots were then washed three times
with PBST, twice with water, and the image captured on an
Odyssey Infrared Imaging System (Li-Cor Biosciences).
Drug Treatment
The CR4 cells were seeded onto the type I collagen-coated 96-
well plates (500 cells/well), cultured in Stemline Pluripotent Stem
Cell Culture media (Sigma) for 2 days, and the treatment was
initiated upon ,90% confluency. Paclitaxel and SBT-1214,
121602 and -12834 were dissolved in sterile DMSO and then
serially diluted in serum-free media. Cells were treated for
48 hours and cell death was analyzed with the MTT assay
[MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] as recommended by manufacturer (Invitrogen).
Statistical Analysis
The dose-response cytotoxicity of new-generation taxoids and
paclitaxel was evaluated by standard MTT assay (all of the in vitro
experiments were repeated at least three times and each
measurement for the MMT assay was performed in 4 repeats).
The dose-response points were plotted as a percentage of the
untreated control, the absorbance of which was considered as
100%. Data were expressed as means 6 SD for each drug
concentration. Similarly, data from at least three different FACS
analyses were also expressed as means 6 SD for each marker. The
statistical significance of differences was determined using the one-
sided Students t-test. P,0.05 was considered statistically signifi-
cant.
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